Interest of in Situ Terlipressin Administration Before the Realisation of Bronchial Biopsy

Inclusion criteria

• Patients ≥18 years old
• Patients scheduled to undergo bronchoscopy, presenting a suspicious radiographic lesion and a lesion proximal tumor pace viewable in white light endoscopy and without pathologic diagnosis
• Patient having read and understood the information letter and signed the consent form
• Effective contraception in women of childbearing age

Exclusion criteria

• Patients with contraindication to the use of terlipressin:
• septic shock ,
• Hypersensitivity to terlipressin or the excipients or by whom use the product is not recommended:
• Recent history (<3 months) of acute coronary syndrome (including myocardial infarction) or unbalanced coronary insufficiency, or disorders of the ventricular heart rate.
• severe uncontrolled hypertension,
• cerebrovascular insufficiency and ischemic stroke of recent origin (<3 months).
• severe arterial occlusive lower extremities,
• severe chronic renal impairment (GFR <20 ml / min).
• Patients receiving uninterrupted antiplatelet therapy during 5 days before endoscopy (7 days for Clopidogrel Related), including low dose aspirin (≤ 75 mg / day).
• Patients receiving anticoagulant therapy:
• Unfractionated heparin within 12 hours before endoscopy.
• low molecular weight heparin within 24 hours before endoscopy.
• Patients with bleeding disorders defined by TP below 70% or TCA ratio patient / control greater than 1.3.
• Patients with thrombocytopenia less than 100 g / L.
• Subjects misunderstanding of spoken and written French
• Person under guardianship or deprived of liberty by judicial or administrative decision (under Article L1121-6 and L1121-8 of Public Health Code
• Pregnant or lactating women, premenopausal women without adequate contraception
• Patient participating in other drug testing or participating in another drug test in the previous month